Vimian Group's Q1 Performance#
Vimian Group AB, a Swedish company specializing in veterinary care, announced its first-quarter revenue of €116 million, reflecting an 8% increase compared to the same period last year. This growth was bolstered by organic growth of 9%, surpassing analysts' expectations by 2%.
Earnings Before Interest, Taxes, and Amortization (EBITA)#
The company reported an adjusted EBITA of €29.2 million, which is a 3% increase year-over-year and 4% above what analysts had predicted. EBITA, which measures a company's overall profitability by focusing on earnings before interest, taxes, and amortization, resulted in a margin of 25.2%, slightly down from 26.3% in Q1 of 2025.
Segment Performance Highlights#
The Diagnostics segment led the way with revenue of €7.1 million, showcasing a 19% growth rate, with 12% of that being organic growth. Veterinary Services generated €17.5 million, marking a 13% increase on a reported basis and 11% organically.
Specialty Pharma recorded €47.6 million in revenue, achieving 10% organic growth, while the MedTech segment brought in €43.9 million with 6% organic growth. The MedTech segment showed signs of recovery, particularly in dental operations and orthopedics outside the United States.
Margin Analysis#
The EBITA margin for Specialty Pharma improved to 30.3%, up from 28.8% in the previous year, thanks to better operational efficiency. Conversely, MedTech's margin decreased to 27.1% from 29.4% due to ongoing investments in growth initiatives within orthopedics. Veterinary Services saw its margin decline to 27.5% from 30.3% as the company expanded into new markets, while Diagnostics' margin slightly decreased to 13.8% from 14.2% due to a less favorable product mix.